Teva Pharmaceuticals to acquire Mexico´s Rimsa for $2.3bn

Teva Pharmaceuticals will pay more than 10 times sales for Mexico´s Representaciones e Investigaciones Médicas SA, or RIMSA.

Goldman Sachs acted as financial adviser to the North American outfit in the sale.

The Israeli generic drugs maker would fork out about $2.3bn for its rival.

The transaction was expected to complete in the early part of 2016 and to contribute to Teva´s earnings starting from the first quarter of 2017.

RIMSA had $227m in sales in 2014.